

# Bicycle

## Bicycle Therapeutics to Host R&D Day on December 14

November 30, 2023

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Nov. 30, 2023-- [Bicycle Therapeutics plc](#) (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (*Bicycle*<sup>®</sup>) technology, today announced that the company will host its first Research and Development (R&D) Day on Thursday, December 14. The event will take place in New York City from 8 a.m. to 12 p.m. Eastern Time and will be simultaneously webcast.

Bicycle Therapeutics executives will provide investors and analysts with an overview of the company's R&D strategy and pipeline opportunities, with an emphasis on clinical updates for BT8009, BT5528 and BT7480. The company will also highlight the broad capabilities of its novel *Bicycle*<sup>®</sup> platform technology.

Analysts and investors who are interested in attending in person should contact [bicycle@argotpartners.com](mailto:bicycle@argotpartners.com). A live webcast of the R&D Day will be accessible from the Investor section of the company's website, [www.bicycletherapeutics.com](http://www.bicycletherapeutics.com). A replay of the webcast will be archived and available following the event.

### About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as *Bicycles*, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making *Bicycles* attractive candidates for drug development. The company is evaluating BT8009, a *Bicycle* Toxin Conjugate (BTC<sup>™</sup>) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2; and BT7480, a *Bicycle* TICA<sup>™</sup> targeting Nectin-4 and agonizing CD137, in company-sponsored Phase 1/2 trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in a Phase 1/2a clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit [bicycletherapeutics.com](http://bicycletherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231130298942/en/): <https://www.businesswire.com/news/home/20231130298942/en/>

### Investors:

Stephanie Yao  
SVP, Investor Relations and Corporate Communications  
[ir@bicycletx.com](mailto:ir@bicycletx.com)  
857-523-8544

### Media:

Argot Partners  
Sarah Sutton  
[media@bicycletx.com](mailto:media@bicycletx.com)  
212-600-1902

Source: Bicycle Therapeutics